This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Single Drugmakers Seek Rich Partners

Big Pharma is in the need of a bailout. Thankfully, Pfizer (PFE), Merck (MRK) and Schering-Plough (SGP) aren't piling into private jets and flying down to D.C. for a public handout.

What the big drug companies should be doing is spending a lot more time around Boston and San Francisco, doling out the cash they do have to smaller biotech firms in need of the green stuff. In exchange, Big Pharma firms get what they desperately need: new drugs to fill the gaping holes that cheaper, generic drugs have created in their pipelines.

By my count (and with the help of a database maintained by BioMedTracker), more than 60 biotech and small drug companies are conducting clinical trials on unpartnered drugs at this time. Surely, some of these companies, not all, will become either alliance or takeover targets for Big Pharma in the next year.

Among the biotech and drug companies on this "singles" list are Allos Therapeutics (ALTH) and its blood cancer drug PDX, Ardea Biosciences (RDEA) and its HIV drug RDEA806 and BioSante Pharmaceuticals (BPAX), which is going to need deep pockets to launch a female sexual dysfunction drug called LibiGel.

Obesity is a growing epidemic in this country, yet three small drugmakers with weight-loss drugs in phase III studies -- Vivus (VVUS - Get Report), Orexigen Therapeutics (OREX) and Arena Pharmaceuticals (ARNA) -- are all without Big Pharma partners.

If Dendreon (DNDN) can prove to the world that its prostate cancer immunotherapy Provenge works, it's not hard to envision the company getting a lot of interest from a large pharmaceutical partner.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DNDN $0.06 -6.02%
INCY $65.51 -9.40%
MDVN $28.60 -2.80%
NBIX $35.37 5.00%
RIGL $2.40 2.60%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs